UTAH DEPARTMENT OF HEALTH, PRIOR AUTHORIZATION REQUEST FORM

Intravitreal Implants

☐ Implant is prescribed by an ophthalmologist.	
Medication Name/ Strength: Directions for use: Provider Information (required) Name: NPI: Specialty: Contact Person: Office Phone: Office Phone: FAX FORM AND RELEVANT DOCUMENTATION INCLUDING: LABORATORY RESULTS, CHART NOTES and/or UPDATED LETTER OF MEDICAL NECESSITY TO 855-828-4992 Criteria for Approval (All must be met): Implant is prescribed by an ophthalmologist.	
Directions for use: Provider Information (required) Name: NPI: Specialty: Contact Person: Office Phone: Office Fax: FAX FORM AND RELEVANT DOCUMENTATION INCLUDING: LABORATORY RESULTS, CHART NOTES and/or UPDATED LETTER OF MEDICAL NECESSITY TO 855-828-4992 Criteria for Approval (All must be met): Implant is prescribed by an ophthalmologist.	
Directions for use: Provider Information (required) Name: NPI: Specialty: Contact Person: Office Phone: Office Fax: FAX FORM AND RELEVANT DOCUMENTATION INCLUDING: LABORATORY RESULTS, CHART NOTES and/or UPDATED LETTER OF MEDICAL NECESSITY TO 855-828-4992 Criteria for Approval (All must be met): Implant is prescribed by an ophthalmologist.	
Provider Information (required) Name: NPI: Specialty: Contact Person: Office Phone: Office Fax: FAX FORM AND RELEVANT DOCUMENTATION INCLUDING: LABORATORY RESULTS, CHART NOTES and/or UPDATED LETTER OF MEDICAL NECESSITY TO 855-828-4992 Criteria for Approval (All must be met): Implant is prescribed by an ophthalmologist.	
Name: NPI: Specialty:	
Contact Person: Office Phone: Office Fax: FAX FORM AND RELEVANT DOCUMENTATION INCLUDING: LABORATORY RESULTS, CHART NOTES and/or UPDATED LETTER OF MEDICAL NECESSITY TO 855-828-4992 Criteria for Approval (All must be met): Implant is prescribed by an ophthalmologist.	
FAX FORM AND RELEVANT DOCUMENTATION INCLUDING: LABORATORY RESULTS, CHART NOTES and/or UPDATED LETTER OF MEDICAL NECESSITY TO 855-828-4992 Criteria for Approval (All must be met): Implant is prescribed by an ophthalmologist.	
CHART NOTES and/or UPDATED LETTER OF MEDICAL NECESSITY TO 855-828-4992 Criteria for Approval (All must be met): Implant is prescribed by an ophthalmologist.	
Criteria for Approval (All must be met): Implant is prescribed by an ophthalmologist.	
☐ Implant is prescribed by an ophthalmologist.	
Additional Criteria for Iluvien (fluocinolone acetonide): All Criteria must be met. Patient must be 18 years or older	
Diagnosis of Diabetic Macular Edema (DME).	
 Previously treated with ophthalmic corticosteroid, without a clinically significant rise in intraocular pressure. Medication Used: Duration of Use: Chart Note Page # 	١.
Medication Used: Duration of Use: Chart Note Page # Patient does not have any of the following contraindicated conditions:	·:
Glaucoma with a cup to disc ratio of greater than 0.8	
Ocular or periocular infections	
Additional Critaria for Occurdor (January), All Critaria month be used. Deticat month to 10 years on additi	
Additional Criteria for Ozurdex (dexamethasone): All Criteria must be met. Patient must be 18 years or older	
 Diagnosis of Diabetic Macular Edema (DME). OR Diagnosis of Macular Edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRV) 	V()\ ()P
Diagnosis of Non-Infectious Uveitis affecting the posterior segment of the eye.	vo). OK
Patient does not have any of the following contraindicated conditions:	
Glaucoma with a cup to disc ratio of greater than 0.8	
Ocular or periocular infections.	
Torn or ruptured posterior lens capsule.	
Additional Criteria for Retisert (fluocinolone acetonide): All Criteria must be met. <i>Patient must be 12 years or older</i>	
Diagnosis of Chronic Non-Infectious Uveitis affecting the posterior segment of the eye for at least 1 year.	
 □ Tried and failed course of Humira (adalimumab) for at least 6 weeks within last year. □ Details of Failure: Duration of Use: Chart Note Page # 	ı .
Details of Failure: Duration of Use: Chart Note Page #	•
Additional Criteria for Yutiq (fluocinolone acetonide): All Criteria must be met. Patient must be 18 years or older	
☐ Diagnosis of Chronic Non-Infectious Uveitis affecting the posterior segment of the eye.	
☐ Tried and failed course of Humira (adalimumab) for at least 6 weeks within last year.	
□ Details of Failure: Duration of Use: Chart Note Page #	:
Authorization: One implant per approval. Reauthorization: Permitted for opposite eye, if treatment of the first eye is successful.	
Reautiforization. Fermitted for opposite eye, if treatment of the first eye is successful.	
PROVIDER CERTIFICATION	
I hereby certify this treatment is indicated, necessary and meets the guidelines for use.	
Prescriber's Signature Date	